Exai: Exai Bio, QLHC announce expanded participation in ISPY 2 trial to advance Exai's novel RNAbased liquid biopsy platform in breast cancer
Exai Bio announced a collaboration agreement with Quantum Leap Healthcare Collaborative (QLHC) to broaden the use of Exai's novel, RNA─based liquid biopsy platform to monitor patients' treatment response
Read full article »
Exai Bio is a California-based biotechnology company that develops oncRNA and AI-driven liquid biopsy technology for the treatment of cancer diagnosis.
Read more